Elias Jabbour

In this discussion, Elias J. Jabbour, a Professor of Medicine at MD Anderson Cancer Center and expert on chronic myeloid leukemia (CML), dives into the intricacies of this disease affecting millions. He highlights the pivotal role of the Philadelphia chromosome in diagnosis and the life-saving impact of tyrosine kinase inhibitors like imatinib. Jabbour also addresses the challenges of medication compliance, therapy resistance, and the evolving criteria for stem cell transplants, painting a comprehensive picture of modern CML management.

Discussing the role of measurable residual disease in ALL treatment, advancements in TKIs for Ph+ ALL, medication-based treatments for high-risk patients, innovative strategies for Ph- leukemia patients, and the importance of achieving MRD negativity in leukemia therapy.

Dr. Elias Jabbour, a leading oncologist from MD Anderson Cancer Center, dives deep into chronic myeloid leukemia (CML) advancements. He reveals exciting findings from the ASCEMBL trial showing asciminib's higher efficacy compared to bosutinib. Jabbour discusses ponatinib's optimized dosing strategy and its effectiveness against specific mutations. He highlights the safety profiles of both drugs, emphasizing considerations for patients at high vascular risk. This insightful talk sheds light on the future of CML treatment decisions.